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Introduction
Annually, the Society for Obstetric Anaesthesia and 
Perinatology recognises Gerard W Ostheimer, a former 
obstetric anaesthesiologist at the Brigham and Women’s 
Hospital in Boston, by presenting an honorary lecture 
that highlights topics relevant to obstetric anaesthesia 
from the obstetrics and anaesthesia literature published 
the previous year. What follows is a brief discussion of the 
topics discussed in the 2011 lecture, namely maternal 
coexisting disease, complications of anaesthesia, the safe 
administration of oxytocin, and patient safety.1
Obesity
The body mass index (BMI) classification remains the preferred 
standard for stratification of maternal body weight, with 
overweight defined as a BMI of 25-29.9 kg/m2, and obesity 
as a BMI of >30 kg/m2. Obesity has been identified as a 
major public health dilemma in the USA, the UK, and most 
of the developed world.1-3 In the USA, the age-adjusted 
prevalence of overweight and obesity among women 
is 64.1%, according to the National Health and Nutrition 
Examination Surgery (NHANES). Other research in the 
USA indicates that 22% of women are obese at the start 
of their pregnancy.1 Among UK women, approximately 
40% were overweight, and 25% were obese, in 2010.2 The 
relevance of these facts to anaesthesia is that in most 
cases, the cumulative effect of the physiological changes 
of pregnancy and obesity alter the anaesthetic plan and 
subsequent management of the parturient. Existing risk 
factors associated with pregnancy are compounded by 
obesity and its associated complications.2 
A thorough pre-clinical assessment is mandatory in the 
obese parturient because of the associated increased 
risk of co-morbid diseases, such as diabetes mellitus, 
hypertension, pre-eclampsia and thromboembolism, 
as well as a higher incidence of maternal and perinatal 
morbidity and Caesarean delivery.3 Obesity has been 
implicated in contributing to maternal mortality in the 
Confidential Enquiry into Maternal and Child Health 
(CEMACH) published in 2007, where more than 50% 
of women who died were reported to be obese or 
overweight.4
Failed intubation occurs in 1 of 280 obstetric patients, 
compared to approximately 1 in 2 500 of the general 
population. In the obese obstetric population, one in 
three women will have a failed intubation.2 Thus, thorough 
airway assessment and planning is crucial for all operative 
procedures in the obese parturient. 
The respiratory changes that are inherent in pregnancy 
are further exaggerated by the presence of obesity. As 
a result of obesity in pregnancy, there is an increased 
ventilation-perfusion mismatch, predisposing hypoxia. 
Breathing work is increased. Obstructive sleep apnoea 
and asthma occur more frequently in obese patients. 
Pulmonary hypertension and cor pulmonale should be 
sought and optimised preoperatively. Postoperatively, 
obese patients have an increased risk of postoperative 
pulmonary complications, such as atelectasis and 
hypoxaemia. They should be given adequate monitoring, 
as well as chest physiotherapy and thromboprophylaxis as 
a priority.
The normal cardiovascular demands of pregnancy 
may be poorly tolerated in the obese parturient with 
co-morbidities associated with obesity. Aortocaval 
compression syndrome is exacerbated in the obese 
mother due to the presence of increased intra-abdominal 
adipose tissue. There is also a higher incidence of 
peripartum cardiomyopathy. 
Some guidelines recommend routine six-hourly prophylaxis 
with ranitidine for women with significant risk who 
require general anaesthesia for surgical intervention, 
for parturients with a BMI > 30kg/m2, for those who have 
had a previous Caesarean delivery, and for women with 
maternal diabetes. 
The overall incidence of anaesthetic complications, 
including failure to establish a neuraxial blockade; failed 
neuraxial anaesthesia, requiring conversion to general 
What’s new in obstetric anaesthesia?
Hlongwane TN
Department of Anaesthesia, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand
Correspondence to: Thenjiwe N Hlongwane, e-mail: thenjiweh@yahoo.co.uk
Keywords: obstetric anaesthesia
© Medpharm S Afr Fam Pract 2012;54(3)(Suppl 1):S11-S13
Anaesthesia Supplement: What’s new in obstetric anaesthesia?
S12 Vol 54 No 3 Supplement 1 S Afr Fam Pract 2012
anaesthesia; and maternal mortality; was 8.4% in a study 
evaluating anaesthesia outcomes during scheduled 
Caesarean deliveries in morbidly obese women.1 
According to Ellinas et al, the odds of a difficult landmark 
palpation are 4.6 times higher in parturients with a BMI of 
35, compared to those with a BMI of 30 kg/m2.1 
Regional anaesthesia is more challenging as a result of 
difficulty in palpating landmarks. The availability of longer 
spinal and epidural needles is necessary to improve 
success rates. General anaesthesia may carry a higher 
risk, due to airway distortion. Practically, dexterity with 
specialised equipment, such as ultrasound, can assist 
with central venous cannulation, as well as repuncture 
lumbar location of landmarks for neuraxial blockade. 
Invasive arterial pressure monitoring allows more accurate 
blood pressure monitoring. Extra-long epidural and spinal 
needles may facilitate the placement of neuraxial blocks.
The leading cause of maternal death in the UK is 
thromboembolic events.4 Thus, it is recommended that 
pregnant women with a BMI of > 30kg/m2, as well as 
two or more risk factors for thromboembolism, should be 
considered for prophylactic low-molecular-weight heparin 
early on in the pregnancy, until six weeks postpartum.4
In summary, obesity increases risk in pregnancy. It is 
important for anaesthetists to have practical skills to 
manage this high-risk group. 
Gestational diabetes mellitus
Gestational diabetes is closely related to maternal obesity, 
and so the co-morbid disease that is often associated 
with obesity as discussed above, needs to be elicited and 
optimised. Patients with diabetes have a higher incidence 
of pregnancy-induced hypertension, polyhydramnios, 
Caesarean section delivery and pre-term labour.3 In a 
study in 2008, the Hyperglycaemia and Adverse Pregnancy 
Outcomes (HAPO) research group demonstrated a strong, 
continuous association between maternal glucose levels 
and adverse pregnancy outcomes. Obese women with a 
BMI > 40kg/m2 had greater odds of having a Caesarean 
delivery. Attenuation of the stress response is important 
in these patients in order to facilitate plasma glucose 
control, so epidural analgesia plays a key role.
Local anaesthetic toxicity1
Although local anaesthetic systemic toxicity (LAST), 
due to epidural anaesthesia, is relatively rare, with an 
estimated incidence of 4 per 10 000, failure to recognise 
and treat the condition promptly can have devastating 
results. Previously, the management of LAST was mainly 
supportive. However, in the past 15 years lipid emulsion 
has emerged as a possible antidote for systemic toxicity. 
The lipid emulsion acts as a “lipid sink” by binding the 
lipid soluble local anaesthetic molecules, thus reducing 
the concentration of tissue-bound local anaesthetic. 
Other theories include possible metabolic alterations in 
mitochondrial metabolism, as well as improved myocyte 
contractility. 
The American Society of Regional Anaesthesia and Pain 
Medicine (ASRA) released a Practice Advisory in 2010 in 
which they recommended prompt airway management 
to prevent hypoxia and acidosis; treatment of seizures with 
benzodiazepines, propofol and thiopental; consideration 
of lipid emulsion administration at the first signs of LAST and 
Advanced Cardiac Life Support (ACLS) in the presence of 
cardiac arrest. Modifications to ACLS include avoidance 
of high-dose adrenaline (< 1 mg/kg) as it may impair the 
function of lipid emulsion in a rodent model, avoiding 
vasopressin because animal models have found poor 
outcomes and pulmonary haemorrhage in the setting 
of lipid emulsion administration, avoiding calcium-
channel and beta adrenergic blockers, and treatment 
of ventricular dysrhythmias with amiodarone, instead 
of local anaesthetics. Both ASRA and the Association 
of Anaesthetists of Great Britain and Ireland (AAGBI) 
recommended the same dosing for 20% lipid emulsion: 
1.5 ml/kg bolus administered over one minute, followed by 
a continuous infusion of 0.25 ml/kg/minute until 10 minutes 
after haemondynamic stability is obtained. Two additional 
boluses may be administered if there is no response 
to the first bolus. The infusion rate may be increased to 
0.5 ml/kg if hypotension persists. The maximum recom-
mended volume is 10 ml/kg in the first 30 minutes.
Maternal aspiration1
Controversy surrounds the question of parturients eating 
light meals during labour. The incidence of pulmonary 
aspiration of gastric contents is 1:661 in patients 
undergoing Caesarean delivery. The increased use of 
neuraxial anaesthesia and improved safety measures, 
such as routine incorporation of antacid prophylaxis as 
premedication prior to Caesarean delivery, has led to a 
decrease in the risk of aspiration in the past three years. 
An analysis of claims against the National Health Service 
in England between 1995-2007 demonstrated no claims 
for maternal aspiration. Instead, complications related to 
neuraxial anaesthesia, such as breakthrough pain, nerve 
damage and back pain. The National Institute for Health 
and Clinical Excellence (NICE) in the UK recommends that 
women in established labour may eat a light meal, unless 
they have received opioids, or are at high risk of having 
a Caesarean delivery. In addition, in a recent Cochrane 
review, there was no evidence of harm from allowing oral 
intake during labour.
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Postdural puncture headache1
Conventional treatment for postdural puncture headache 
(PDPH) is conservative. It includes bed rest, fluids, oral 
caffeine, and nonsteroidals with use of an epidural blood 
patch if these measures fail. Recent case reports have 
described the use of adrenocorticotropic hormone (ACTH) 
in the form of cosyntropin (a synthetic ACTH analogue) 
for the treatment of PDPH. The potential mechanisms of 
action include ACTH-stimulated aldosterone release, 
which enhances salt and water retention, thus causing 
an increase in the circulating blood volume. This leads to 
dural oedema, or closure of the dural puncture, increased 
cerebrospinal fluid production, or an increase in the beta 
endorphins, which decreases the pain perception. A 
recent study showed a decreased need for an epidural 
blood patch in women receiving 1 mg of cosyntropin after 
unintentional dural puncture. Although this drug shows 
promise, further studies are required to evaluate the safety 
of cosyntropin in the postpartum period.
Oxytocin1
Oxytocin is administered prophylactically to prevent 
postpartum haemorrhage after delivery. The optimum 
dose and method of delivery thereof, remains unclear. 
Many guidelines recommend 5 units of oxytocin as an 
intravenous bolus after umbilical cord clamping, to 
prevent postpartum haemorrhage. A study by Butwick et 
al failed to demonstrate a difference in uterine tone scores 
six minutes after administration of oxytocin between the 
groups, who were given 0, 0.5, 1, 3, or 5 international units 
of oxytocin.1
King et al did not suggest any benefit to administration of 
oxytocin bolus before an infusion of oxytocin in women 
at high risk of postpartum haemorrhage. ST-segment 
depression is the most serious observed side- effect of 
oxytocin administration, even though it is unclear whether 
or not these changes are indicative of myocardial 
ischaemia. In a study by Jonsson et al, the incidence of ST 
depression associated with oxytocin bolus administration 
was lower in the group receiving 5 IU, compared to the 
group given 10 IU. 
Thus, although it remains unclear what the optimal dose 
and method of administration of oxytocin is, it is prudent 
to give the lowest effective dose of oxytocin in order to 
avoid iatrogenic injury.
Patient safety checklists1
Currently, significant research is being carried out to 
determine the role of checklists in improving patient 
outcomes. The World Health Organization’s (WHO) Safe 
Surgery Saves Live study has demonstrated a decrease 
in complications following its introduction. A number of 
checklists have been developed for research in obstetric 
anaesthesia. However, further research is still needed to 
evaluate their effect on patient outcome.
Conclusion
Co-morbid disease in pregnancy increases the risk 
of anaesthesia significantly. It remains incumbent on 
the anaesthetist to ensure that he or she has the skills 
and dexterity with specialised equipment to manage 
such patients optimally, to ensure the safety of both 
the mother and the child. Advances in the area of 
LAST management mandate a familiarity with the use 
of lipid emulsion for anaesthetists performing epidural 
anaesthesia and analgesia in parturients. Cosyntropin 
is emerging as a possible prophylactic agent for PDPH, 
although more research is still needed into its use for 
prophylaxis. The lowest possible dose of oxytocin should 
be used to balance the side-effects of the drug against 
optimal uterine tone. Surgical safety checklists that are 
specific to obstetric practice are still undergoing research, 
but existing checklists, such as the WHO Surgical Safety 
Checklist, may still be of use in the interim.
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